Added to YB: 2025-10-09
Pitch date: 2025-10-07
TLX.AX [neutral]
Telix Pharmaceuticals Limited
-18.02%
current return
Author Info
No bio for this author
Company Info
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
Market Cap
AUD 3.3B
Pitch Price
AUD 15.32
Price Target
N/A
Dividend
N/A
EV/EBITDA
87.60
P/E
228.98
EV/Sales
5.29
Sector
Biotechnology
Category
special_situation
Telix Pharma (TLX AU) - TLX591 trial
TLX.AX (overview): TLX591 prostate cancer drug derived from repeatedly failed Huj591 (2001 Takeda trial missed primary endpoint, 2013 Ph2 failed w/ p=1.00). Current Ph3 readouts pushed from 1H25 to 2H25 w/o explanation. SEC subpoena on disclosures. Slow enrollment (2.5 pts/month vs planned). Competing vs NOVN's Pluvicto in tough market.
Read full article (4 min)